Standard Family Office’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-377
| Closed | -$40K | – | 296 |
|
|
2022
Q3 | $40K | Hold |
377
| – | – | 0.02% | 151 |
|
|
2022
Q2 | $37K | Buy |
+377
| New | +$37K | 0.37% | 65 |
|
|
2022
Q1 | – | Sell |
-525
| Closed | -$45K | – | 179 |
|
|
2021
Q4 | $45K | Buy |
+525
| New | +$45K | 0.4% | 57 |
|
|
2021
Q3 | – | Sell |
-663
| Closed | -$65K | – | 366 |
|
|
2021
Q2 | $65K | Hold |
663
| – | – | 0.01% | 225 |
|
|
2021
Q1 | $64K | Hold |
663
| – | – | 0.02% | 239 |
|
|
2020
Q4 | $64K | Buy |
+663
| New | +$64K | 0.02% | 242 |
|